{
    "nct_id": "NCT04910425",
    "official_title": "Phase II Study to Evaluate the Performance of PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Clinically Significant Prostate Cancer in Men Presenting Following a Positive Screen for Prostate Cancer",
    "inclusion_criteria": "* Patients must have a positive screen for prostate cancer as confirmed by a prostate specific antigen (PSA) >= 2 ng/ml\n* Patients must elect to elect to undergo PHI blood test and TRUS-guided elect to undergo PHI blood test and TRUS-guided biopsy as part of routine clinical care\n* Patients must be age >= 18 years\n* Patients must agree to use adequate contraception (e.g. Barrier method of birth control; abstinence) for 24 hours following completion of imaging\n* Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who have had a prior biopsy for prostate cancer\n* Patients who have contraindications to MRI (i.e. pacemakers, aneurysm clips or shaped fragments) are not eligible\n* Patients receiving any other treatments or investigational agents are not eligible\n* Patients with a glomerular filtration rate (GFR) < 30mL/min are ineligible to receive intravenous contrast per standard magnetic resonance (MR) exclusion criteria\n* Patients administered a radioisotope < 5 physical half-lives prior to the date of study PET/MRI\n* Patients administered IV X-ray contrast medium < 120 hours prior to the date of study PET/MRI\n* Patients who report taking multivitamins on the day of study PET/MRI",
    "miscellaneous_criteria": ""
}